October 3rd 2025
Alto Neuroscience's ALTO-101 gains FDA Fast Track designation, promising a novel treatment for cognitive impairment in schizophrenia.
Recovery From “Schizophrenia”: One Man’s Journey From Patient to Therapist
October 30th 2014“Schizophrenia” is a name, not a disease. You are about to read the life story of a remarkable man who describes how he overcame poverty, orphanhood, and schizophrenia to become an author, an LCSW, a leader in the mental health advocacy movement, and an inspiration for many others.
Read More
6 Practical Tips for Treating Schizophrenia Comorbid With Obsessive-Compulsive Disorder
October 3rd 2014Despite the growing body of evidence that supports the existence of a specific epidemiological, genetic, and neurobiological relationship between OCD and schizophrenia, the association remains poorly understood. Here, a brief overview.
Read More
Tipsheet: Sleep Disturbances in Psychiatric Illness
August 1st 2014Most patients with psychiatric diagnoses present with sleep disturbances that can have as great an impact on health-related quality of life as the mental illness itself. Here are tips on treatment and chronotherapeutic applications for major depression and other disorders.
Read More
Harnessing the Innate Plasticity of the Brain for Recovery
May 27th 2014We talk about mental disorders as brain disorders, but what does that really mean? How does it change the way we think about autism, schizophrenia, depression, bipolar, and other illnesses? The answer to these questions are still evolving. More in this video exclusive with NIMH Director Thomas Insel, MD.
Read More
Integrative Management of Schizophrenia
May 13th 2014Select natural products have been evaluated as adjunctive agents that may be combined with conventional antipsychotics, with promising preliminary findings. Music therapy, meditation, and mindfulness training may improve quality of life for individuals with schizophrenia. Details here.
Read More
ECT and Catatonia: Out of the Shadows
December 26th 2013Catatonia-a syndrome of disturbed motor, mood, and systemic signs (eg, rigidity, immobility, mutism, staring, posturing, waxy flexibility, echopraxia, echolalia, and stereotypies)-has led to the clarification of its appropriate treatment.
Read More
Psychosis Risk Syndrome Is Back
November 26th 2013"Psychosis Risk" can now be diagnosed as “Attenuated Psychosis Syndrome” and used to bill for insurance reimbursement. Many bearing the diagnostic label are young adolescents and adults in whom schizophrenia or any other psychotic disorder will never develop.
Read More
Risperdal Maker Pays High Price to Resolve Criminal and Civil Investigations
November 8th 2013Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by FDA and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.
Read More